Applied Phenomics will provide Xantos with its methodological base and clinical genomics resources for validation of novel targets identified using cell-based screening approach
Xantos Biomedicine, a functional biology and drug discovery company based in Munich, Germany, and Applied Phenomics, a privately-held clinical genomics company based in Tartu, Estonia, have announced that Applied Phenomics will provide Xantos with its methodological base and clinical genomics resources for validation of novel targets identified using Xantos cell-based screening approach.
Xantos uses its Xantoscreen technology to discover and functionally validate novel targets on a genome-wide basis.
For further validation of these targets on clinical samples access to high-quality and flexible set of services offered by Applied Phenomics is of key importance.
In the framework of the collaboration, Applied Phenomics uses its Phenomax tissue arrays for optimisation of anti-target immunostaining in normal tissues, and performs target immunolocalisation in tumour samples under optimised conditions. These studies are complemented with in situ hybridisation studies and interpreted in the context of immunostainings with selected diagnostic antibodies from Applied Phenomics stock.
"Xantos focuses on the development of novel therapeutic proteins and drugs in the field of cancer and metabolic diseases. "Validation of our novel targets in well documented clinical samples is of importance for us.
"Together with Applied Phenomics we work out detailed project procedures and we are very satisfied with the care they took to generate the data. "Their in-depth knowledge of target validation by histological methods effectively supports our development process." stated Ulrich Brinkmann, CSO at Xantos Biomedicine.
"Our combination of state-of-the-art molecular biology and clinical pathology expertise and research-grade ethically sound tissue samples forms a solid basis for validation of targets identified in in vitro screens" stated Tambet Teesalu, CEO at Applied Phenomics.
"We are very pleased to be working with Xantos and contribute to the success of their drug development programmes".
